RXi Pharmaceuticals Corporation Company Profile

RXi Pharmaceuticals is a recognized leader in RNAi-based therapeutic discovery and development with a comprehensive therapeutic platform that includes both RNA interference (RNAi) compounds and delivery methods. The company is leveraging this broad and integrated RNAi therapeutic platform to build a pipeline of RNAi therapeutics for the treatment of a number of disease areas, including its core focus of developing treatments for anti-scarring and retinal disorders as well as a continued interest in oncology and indications accessible by spinal cord delivery. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi therapeutics market based on the strength of its next generation therapeutic platform, experienced management team, accomplished Scientific Advisory Board, including Nobel Laureate, Dr. Craig Mello, and its broad intellectual property position in RNAi chemistry and delivery. www.rxipharma.com

More Information about "RXi Pharmaceuticals Corporation" on BioPortfolio

We have published hundreds of RXi Pharmaceuticals Corporation news stories on BioPortfolio along with dozens of RXi Pharmaceuticals Corporation Clinical Trials and PubMed Articles about RXi Pharmaceuticals Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of RXi Pharmaceuticals Corporation Companies in our database. You can also find out about relevant RXi Pharmaceuticals Corporation Drugs and Medications on this site too.